Table: A Windfall In The Making

Pharmaceutical makers are seeking an average of 12 months' extra protection 
      from generic competitors for more than 100 drugs
      DRUG                 MONTHS           POTENTIAL EXTRA REVENUES
      COMPANY/            OF ADDED          BECAUSE OF LACK
      USE                PROTECTION         OF GENERIC ALTERNATIVE
                      MILLIONS OF DOLLARS
      ZANTAC                  19           $1,000
      Glaxo/ulcers 
      MEVACOR                 19             $448
      Merck/
      cholesterol-lowering 
      DIFLUCAN                20             $410
      Pfizer/
      antifungal agent
      PRILOSEC                17             $586
      Merck/ulcers
      CAPOTEN                  6             $101
      Bristol-Myers
      Squibb/hypertension
      DATA: PRIME INSTITUTE, UNIVERSITY OF MINNESOTA
      
Before it's here, it's on the Bloomberg Terminal.
LEARN MORE